NEW YORK (GenomeWeb) – Genomic Health said today that it has signed a multi-year research collaboration agreement with Janssen Pharmaceuticals in which the companies will evaluate Genomic Health's Oncotype DX Genomic Prostate Score as a predictor of response to prostate cancer drugs in Janssen's pipeline.

Under the terms of the agreement, Genomic Health will test samples from studies Janssen is conducting to examine the association of GPS results with clinical outcomes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.